Evidence map›Paper›PMID 38633575›Full record

ArticleEClinicalMedicine2024

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.

Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti and 25 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02904577 (Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02904577 completednot on this map

Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas

TypeobservationalSponsorFondazione Italiana Linfomi - ETSRan2011 to 2024Enrolled370ConditionsIndolent B-Cell LymphomasArmsAny treatment, watch and wait policy included
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Prognostic Significance of Paraproteinemia in Marginal Zone LymphomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 4 countries.

Luca ArcainiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Côme BommierHemato-Oncology Department, DMU DHI, Hôpital Saint Louis, Paris, France.
Juan Pablo AlderuccioDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Michele MerliDivision of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria, Varese, Italy.
Nicole FabbriDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Maria Elena NizzoliDivision of Hematology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
Matthew J MaurerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Vittoria TarantinoDivision of Hematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Simone FerreroDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, and AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
Sara RattottiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Annalisa TalamiClinical and Experimental Medicine Doctorate School, Università degli Studi di Modena e Reggio Emilia, Italy.
Roberta MurruHematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu, Cagliari, Italy.
Arushi KhuranaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Raphael MwangiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Marina DeodatoDivision of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Emanuele CenciniDivision of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy.
Francesca ReDivision of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Carlo ViscoDivision of Hematology, San Bortolo Hospital, AULSS 8 Berica, Vicenza, Italy.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Brian K LinkDepartment of Internal Medicine, University of Iowa Hospitals, Iowa City, IA, USA.
Marcia Torresan DelamainFaculty of Medical of Minas Gerais, Feluma, Brazil for Faculty of Medical of Minas Gerais, Belo Horizonte, Brazil.
Michele SpinaDivision of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Ombretta AnnibaliDivision of Hematology, Stem Cell Transplantation, University Campus Bio-Medico, Roma, Italy.
Alessandro PulsoniDivision of Hematology, Sapienza University - Polo Pontino, Department of Translational and Precision Medicine, S.M. Goretti Hospital, Latina, Italy.
Andrés J M FerreriLymphoma Unit, IRCCS San Raffaele Scientific Institute, and University Vita-Salute San Raffaele, Milano, Italy.
Caterina Cecilia StelitanoDivision of Hematology, Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Calabria, Reggio Calabria, Italy.
Elsa PenneseDivision of Hematology, Ospedale Spirito Santo, Pescara, Italy.
Thomas M HabermannDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Luigi MarcheselliFondazione Italiana Linfomi ETS, Italy.
Sunwoo HanBiostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Isildinha M ReisBiostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Marco PaulliDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Izidore S LossosDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
James R CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Stefano LuminariDivision of Hematology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
Mayo Clinic in Arizona · USUniversity of Miami · USUniversity of Modena and Reggio Emilia · ITUniversity of Pavia · ITMayo Clinic in Florida · USAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera G. Brotzu · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITCentro di Riferimento Oncologico · ITFaculdade de Ciências Médicas de Minas Gerais · BRFondazione Intergruppo Italiano Linfomi Onlus · ITHôpital Saint-Louis · FROspedale di Parma · ITOspedale di Santo Spirito · ITOspedale San Bortolo · ITOspedale Santa Maria Goretti · ITOspedale Vincenzo Cervello · ITPoliclinico San Matteo Fondazione · ITUniversità Campus Bio-Medico · ITUniversity of Insubria · IT

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
NCI NIH HHS P50 CA097274NCI NIH HHS U01 CA195568
6 · The paper itself

Abstract

Background: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. Methods: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment. The model was externally validated in a pooled analysis of two independent cohorts from the University of Iowa and Mayo Clinic Molecular Epidemiology Resource and the University of Miami. Findings: We identified 501 eligible patients. After multivariable modeling, lactate dehydrogenase (LDH) above upper normal limit, hemoglobin <12 g/dL, absolute lymphocyte count <1 × 10 Interpretation: MZL-IPI is a new prognostic score for use in all patients with MZL considered for systemic treatment. Funding: The MER was supported by P50 CA97274 and U01 CA195568.

Indexed as

Marginal zone lymphomaPrognosis

Identifiers

PMID38633575
PMCPMC11019091
OpenAlexW4394711097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.